Leading in Cell and Gene Therapy CDMO
Service
Excellence
Leading in Cell and Gene Therapy CDMO
Innovative
Solutions
scroll down
ENCELL Co. Ltd. offers
contract development and manufacturing (CDMO) services
and contract quality testing (CQT) services
through the operation of globally recognized GMP facilities.
CDMO
The ROCKET Platform represents a multi-product
GMP production technology-based CDMO service.
Through the operation of globally recognized GMP facilities,
ENCELL has enhanced its quality management and capabilities,
thereby establishing the capacity to secure contracts for global products.
CQT Services
Raw materials during the manufacturing process:
IPC, DS/DP, stability testing
At ENCELL Co., Ltd., we conduct comprehensive quality and
characterization testing for all samples generated during
the production process, including raw materials, IPC, and DS/DP.
This allows us to guarantee the highest quality standards for our products.
Our mission is to elevate
the quality of advanced biopharmaceuticals through
the application of cutting-edge technology and expertise.
Research Center
CDMO and Contract Quality Services for Cell and Gene Therapies
Our research center is a leading provider of contract research
and quality assurance services for cell and gene therapies.
We specialize in GMP production processes and quality analysis development,
as well as cell characterization and mechanism studies.
Platform Technology
Our platform technology leverages next-generation
stem cell technology to achieve high yields and efficacy.
ENCELL's innovative platform technology addresses key challenges
in cell aging, efficacy, and high-yield production,
offering a cost-effective solution to enhance productivity and profitability.
Pipeline
The Pipeline Overview demonstrates
ENCELL's technological capabilities.
Our company is committed to developing cutting-edge therapeutic products,
including next-generation stem cell therapies, cancer immunotherapy cell treatments,
and AAV-based gene therapies.
Company Information
.jpg)
ENCell Co., Ltd. Selected for the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program
ENCell Co., Ltd. has been selected as a final participant in the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program. The selected project is titled "Development of a Treatment for Duchenne Muscular Dystrophy Utilizing High-Potency/High-Efficiency GMP Technology for Large-Scale Expansion of Early-Passage Umbilical Cord-Derived Mesenchymal Stem Cells." ENCell Co., Ltd. will serve as the lead organization (Project Manager: CEO Jongwook Jang), with Samsung Medical Center participating as a collaborating institution (Division Manager: Professor Jihoon Lee, Department of Pediatrics).Through this project, ENCell aims to accelerate clinical trials and commercialization of its stem cell-based treatment for Duchenne Muscular Dystrophy. By securing funding support from Seoul City, the company is committed to contributing to the growth of Seoul’s bio-medical industry and pledges to dedicate itself to the development of therapies for the rare disease Duchenne Muscular Dystrophy.